A comparison between two induction regimes for the interferon treatment of chronic hepatitis C. Response related factors

Revista Espanola de Enfermedades Digestivas

Volumn 89, Issue 3, 1997, Pages 167-173

  Perez R ^a   Pravia, R ^a   Artimez M L ^a   Linares, A ^a   Lombrana J L S ^a   Perez Lopez R ^a   Rodrigo, L ^a   San Miguel, G ^b   Pons, F ^b   Suarez F ^c   Caro Paton A ^d  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

alfa interferon; HCV; hepatitis C; response; treatment

Indexed keywords

ALPHA INTERFERON; INTERFERON; RECOMBINANT ALPHA2B INTERFERON; ALPHA2B INTERFERON; ANTINUCLEAR ANTIBODY; FERRITIN; IRON;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; ADOLESCENT; AGED; BLOOD; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; TIME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRITINS; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERONS; IRON; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0031091205     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Tinè F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomized clinical trials. J Hepatol. 1991;13:192-199.
2. Gómez Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreño V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant α-interferon in comparison with a control group. J Hepatol. 1990;11:S63-S67.
3. Sáez-Royuela F, Porres JC, Moreno A, et al. High doses of recombinant α-Interferon or γ-Interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology. 1991;13:327-331.
4. Ferenci P, Vogel W, Pristautz H, et al. One year treatment of chronic hepatitis with Interferon alfa-2b. J Hepatol. 1990;11:S50-S53.
5. Reichard O, Foberg V, Frydén A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α2b for 60 weeks. Hepatology. 1994;19:280-285.
6. Yokosuka O, Kato N, Hosoda K, et al. Efficacy of long-term interferon treatment in chronic liver disease evaluated by sensitive polymerase reaction assay for hepatitis C virus RNA. Gut. 1995;37:721-726.
7. Saracco G, Rosina F, Torrani Cerenzia MR, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A. non-B hepatitis. J Hepatol. 1990;11: S43-S49.
8. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kierman TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
9. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med. 1989; 321:1501-1506.
10. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 1991;101:497-502.
11. Marcellin P, Boyer N, Giostra E, et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 1991;13:393-397.
12. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C: Hepatology. 1995;22:700-706.
13. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatits C treated with α-interferon. Hepatology. 1992;15:1013-1016.
14. Hagiwara H, Hayashi N, Mita E, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α. Hepatology. 1992;15:37-41.
15. Lebovics E, Lantin J, Chaurushia G, Dworkin BM, Casellas A, Rosenthal WS. The breakthrough phenomenon during α-interferon therapy of chronic hepatitis C: incidence, management, and outcome. Amer J Gastroenterol. 1995; 90:951-954.
16. Pérez R, Pravia R, Linares A, et al. Response related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C: Gut. 1993;34(Suppl 2):S139-S140.
17. Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstal R, Fryden A. Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis. Liver. 1991;11:30-38.
18. Pérez R, Pravia R, Linares A, et al. Treatment of chronic hepatitis C with recombinant interferon alfa-2b for nine months. Gut. 1993:34(Suppl 2):S136-S138.
19. Pérez Alvarez R. Factores relacionados con la respuesta al interferon en la hepatitis crónica C: Gastroenterol Hepatol. 1996;19:217-223.
20. Lin R, Liddle C, Byth K, Farrell GC. Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C: J Viral Hepatitis. 1996;3:85-96.
21. Cammà C, Craxi A, Tinè F, et al. Predictors of response to alpha-interferon (IFN) in chronic hepatitis C: a multivariate analysis on 361 treated patients. Hepatology. 1992;16: 131A.
22. Camps J, Crisóstomo S, García-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut. 1993;34:1714-1719.
23. Serfaty L, Giral P, Loria A, Andréani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C: J Hepatol. 1994;21:12-17.
24. Davis GL, Lindsay K, Albrecht J, et al. Clinical predictors of response to recombinant interferon-α treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). J Viral Hepatitis. 1994;1:55-63.
25. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C: Hepatology. 1995;22:1050-1056.
26. Jouet P, Roudot-Thoraval F, Dhumeaux D, et al. Comparative efficacy of interferon alpha in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology. 1994;106:686-690.
27. Sánchez-Tapias JM, Barrera JM, Costa J, et al. Hepatitis C virus infection in patients with nonalcoholic chronic liver disease. Ann Intern Med. 1990;112:921-924.
28. Czaja AJ, Taswell HF, Rakela J, Schimek C. Frequency of antibody to hepatitis C virus in asymptomatic HBsAg-negative chronic active hepatitis. J Hepatol. 1992;14:88-93.
29. Vento S, Di Perri G, Garofano T, et al. Hazards of interferon therapy for HBV-seronegative chronic hepatitis. Lancet. 1989;2:926.
30. Saracco G, Touscoz G, Durazzo M, et al. Autoantibodies and response to α-interferon in patients with chronic viral hepatitis. J Hepatol. 1990;11:339-343.
31. Olaso V, Siles M, Córdoba J, et al. Prevalencia y significatión clínica de los autoanticuerpos en la hepatitis crónica C tratada con interferón alfa. Rev Esp Enf Digest. 1995;87:577-581.
32. García-Buey L, García-Moazón C, Rodríguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C: Gastroenterology. 1995;108:1770-1777.
33. Prieto J, Barry M, Sherlock S. Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology. 1975;68:525-533.
34. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 1992;102:2108-2113.
35. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology. 1993;104:877-883.
36. Yamada G, Takatani M, Kishi F, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology. 1995;22:1351-1354.
37. Leiva PS, Pérez R, Méndez J, Santos-Rionda MJ. Recombinant α-2b interferon therapy for chronic hepatits C: genotypes and viraemia evolution. Abstracts of the 35 th ICAAC. San Francisco 1995, H87.
38. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology. 1995; 21:291-297.
39. Fattovich G, Giustina G, Favarato S, Ruol A and Investigators of the Italian Association for the Study of the Liver. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24:38-47.